Aging & Senescence

Why do we age? The question is deeper than it sounds. From an evolutionary perspective, aging is not an obvious feature for natural selection to produce — organisms that don't deteriorate would, all else equal, leave more descendants. Yet almost all multicellular life shows progressive deterioration culminating in death, with characteristic species-specific lifespans ranging from days (mayflies) to centuries (Greenland sharks, bristlecone pines). The modern theory of aging — assembled across the twentieth century by Peter Medawar, George Williams, and Tom Kirkwood — explains why selection allows aging to exist; the contemporary biology of aging focuses on how it happens at the molecular and cellular level, and increasingly whether and how it can be slowed. The 2013 paper The Hallmarks of Aging (López-Otín et al.) compressed decades of work into a taxonomy of nine (later twelve) interlocking processes and made aging biology one of the most active research frontiers in medicine.

The evolutionary theory of aging rests on three connected ideas: Medawar's mutation accumulation (1952) — selection's strength weakens with age (most reproduction has occurred by mid-life), so deleterious mutations whose effects manifest only late are less strongly purged; Williams's antagonistic pleiotropy (1957) — alleles that help reproduction in youth but harm survival in old age can be positively selected because youth-fitness gains outweigh old-age losses; and Kirkwood's disposable-soma theory (1977) — selection apportions limited resources between reproduction and somatic maintenance to maximize lifetime reproductive success, sacrificing some maintenance for reproductive output. The molecular hallmarks of aging (López-Otín et al. 2013, updated 2023) identify twelve interlocking processes. Several recur through the rest of the story: genomic instability and telomere attrition as DNA and chromosome ends degrade; deregulated nutrient sensing (insulin/IGF-1, mTOR, AMPK signaling — the most modifiable hallmark); mitochondrial dysfunction; and cellular senescence, whose senescence-associated secretory phenotype releases the inflammatory factors behind age-related chronic inflammation. These hallmarks are interconnected — telomere shortening triggers senescence, senescent cells produce inflammation, inflammation drives further damage, mitochondrial decline impairs proteostasis — and the major lifespan-extending interventions in model organisms all hit these pathways. Caloric restriction extends lifespan across yeast, worms, flies, and mice through nutrient-sensing pathways; rapamycin (an mTOR inhibitor) extends it in mice even when started in middle age; metformin is in human trials (TAME); senolytics selectively kill senescent cells and extend healthspan in mice; and Yamanaka-factor reprogramming can reverse some aging hallmarks in mice, with partial-reprogramming protocols an active frontier.